Loading company…
Wayfinder Biosciences develops RNA-targeting therapies for neurodegenerative and other diseases.
Founded in 2021 and based in Seattle, US, Wayfinder Biosciences develops small molecules that bind to specific mRNAs to prevent production of harmful proteins. Its research targets neurodegenerative diseases and other conditions linked to protein dysregulation, as well as oncology and rare diseases. In October 2022, it raised USD 3.5 mn in Seed funding co-led by Divergent Capital Partners and Notation Capital, with participation from BoxOne Ventures and SOSV.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in